Cannabigerol

Cannabigerol at a Glance

Cannabigerol (CBG) is the “mother cannabinoid” — its acidic form, CBGA, is the biosynthetic precursor from which the plant makes THC, CBD and CBC. What remains in a mature plant is whatever was not converted.

It is non-intoxicating, and its pharmacology is unlike the better-known cannabinoids: a distinctive alpha-2-adrenoceptor and TRP-channel profile, which is closer to clonidine’s target than to THC’s.

It is now one of the few minor cannabinoids with any human data at all — two small studies, published two years apart, which reached different conclusions.

What “Mother Cannabinoid” Actually Means

The phrase is used loosely in marketing and is worth pinning down, because it describes a real and unusual relationship.

Cannabis makes cannabigerolic acid (CBGA) first, by attaching a geranyl group to olivetolic acid. CBGA is then the single substrate that three enzymes compete for: THCA synthase routes it to tetrahydrocannabinolic acid ^{9Reference 9Sirikantaramas S et al. · 2004The gene controlling marijuana psychoactivity: molecular cloning and heterologous expression of Δ1-tetrahydrocannabinolic acid synthase from Cannabis sativa LView study →}, CBDA synthase to cannabidiolic acid ^{8Reference 8Taura F et al. · 1996Purification and characterization of cannabidiolic-acid synthase from Cannabis sativa L.: biochemical analysis of a novel enzyme that catalyzes the oxidocyclization of cannabigerolic acid to cannabidiolic acidView study →}, and CBCA synthase to cannabichromenic acid ^{11Reference 11Fulvio F et al. · 2021Analysis of sequence variability and transcriptional profile of cannabinoid synthase genes in Cannabis sativa L. chemotypes with a focus on cannabichromenic acid synthaseView study →}. Which of those a plant expresses, and how strongly, is what a chemotype is — CBDA synthase in particular is described as the chemotype-determining enzyme of fibre-type cannabis ^{10Reference 10Taura F et al. · 2007Cannabidiolic-acid synthase, the chemotype-determining enzyme in the fiber-type Cannabis sativaView study →}.

Two consequences follow, and the second is the one that gets lost.

CBG in a mature plant is unconverted leftover. A high-THC or high-CBD plant runs most of its CBGA down one branch, so what remains as CBG is what the synthases did not reach. That is why CBG content falls as a plant matures, and why early-harvested material is richer in it.

A CBG-dominant plant is a plant whose synthases do not work. Cultivars sold as high-CBG accumulate the precursor because the downstream enzymes are absent or non-functional, not because they make more of it. The molecule is not a product being manufactured; it is a queue that never cleared.

CBG is therefore the only major cannabinoid whose abundance is set by the absence of an enzyme rather than the presence of one.

Clonidine’s Target, Not THC’s

CBG’s receptor profile has almost nothing in common with the cannabinoid it is sold beside.

Its most striking property is that it is a highly potent α2-adrenoceptor agonist, and a moderately potent 5-HT1A antagonist ^{1Reference 1Cascio MG et al. · 2010In vitroEvidence that the plant cannabinoid cannabigerol is a highly potent α2-adrenoceptor agonist and moderately potent 5HT1A receptor antagonist — in vitroView study →}. The α2-adrenoceptor is the target of clonidine and dexmedetomidine — drugs used for blood pressure, sedation and opioid withdrawal — and it is not a cannabinoid target at all. Alongside that, CBG has a defined TRP-channel profile: TRPA1 and TRPV1 agonism, TRPM8 antagonism ^{3Reference 3De Petrocellis L et al. · 2011In vitroEffects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes — in vitroView study →}. Its affinity for CB1 and CB2 is weak, which is why it does not intoxicate.

The 5-HT1A direction is worth noting because it is the opposite of CBD’s. CBD is a 5-HT1A agonist; CBG is an antagonist ^{1Reference 1Cascio MG et al. · 2010In vitroEvidence that the plant cannabinoid cannabigerol is a highly potent α2-adrenoceptor agonist and moderately potent 5HT1A receptor antagonist — in vitroView study →}. Two non-intoxicating cannabinoids marketed for overlapping calm-and-focus purposes act in opposite directions at the same serotonin receptor.

That profile predicts cardiovascular and sedative interactions rather than cannabinoid ones — and it is the reason the interaction cautions on this molecule are about blood-pressure and sedative medication rather than about CYP450 enzymes.

What It's Used For

CBG’s pharmacology is preclinical almost everywhere, with one important exception: two small human studies have now been published, and they disagree. A double-blind placebo-controlled crossover field trial found 20 mg reduced anxiety and stress ^{5Reference 5Cuttler C et al. · 2024RCTAcute effects of cannabigerol on anxiety, stress, and mood: a double-blind, placebo-controlled, crossover, field trialView study →}; a single-ascending-dose laboratory study at 25–200 mg found no robust pharmacodynamic effects at any dose ^{6Reference 6Wolinsky D et al. · 2026Clinical trialSafety, pharmacodynamics, and pharmacokinetics of oral cannabigerol in healthy adults — human studyView study →}. Both were small, and neither has been replicated.

Evidence by IndicationStrength of support · Beta

01Anxiety & stressShaky44%One positive human crossover trial, contradicted by a dose-ranging laboratory study ^{5,6Reference 5Cuttler C et al. · 2024RCTAcute effects of cannabigerol on anxiety, stress, and mood: a double-blind, placebo-controlled, crossover, field trialView study →Reference 6Wolinsky D et al. · 2026Clinical trialSafety, pharmacodynamics, and pharmacokinetics of oral cannabigerol in healthy adults — human studyView study →}

02Anti-inflammatory (gut)Shaky42%Mouse colitis model; anti-inflammatory + antioxidant ^{2Reference 2Borrelli F et al. · 2013AnimalBeneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease — mouse colitis modelView study →}

03Appetite stimulationShaky40%Rat feeding study plus a human appetite signal at 200 mg ^{4,6Reference 4Brierley DI et al. · 2016AnimalCannabigerol is a novel, well-tolerated appetite stimulant in pre-satiated rats — rat feeding modelView study →Reference 6Wolinsky D et al. · 2026Clinical trialSafety, pharmacodynamics, and pharmacokinetics of oral cannabigerol in healthy adults — human studyView study →}

Mechanisms

Clinical trials

CBG has two completed human studies — one crossover field trial of a single 20 mg dose ^{5Reference 5Cuttler C et al. · 2024RCTAcute effects of cannabigerol on anxiety, stress, and mood: a double-blind, placebo-controlled, crossover, field trialView study →} and one single-ascending-dose laboratory study across 25–200 mg ^{6Reference 6Wolinsky D et al. · 2026Clinical trialSafety, pharmacodynamics, and pharmacokinetics of oral cannabigerol in healthy adults — human studyView study →} — and no completed efficacy trial in any patient population. Everything else is preclinical.

Last checked: September 2026.

Pharmacokinetics

Until 2026 there was no human pharmacokinetic data for CBG at all. There is now one dataset, and its main message is variability.

Twelve healthy adults were given 0, 25, 50, 100 and 200 mg of CBG isolate suspended in medium-chain triglyceride oil, with plasma sampled over eight hours. Pharmacokinetics were dose-orderly — exposure rose with dose — but with substantial variability between individuals ^{6Reference 6Wolinsky D et al. · 2026Clinical trialSafety, pharmacodynamics, and pharmacokinetics of oral cannabigerol in healthy adults — human studyView study →}. Liver function tests stayed within normal limits after the two highest doses, and no drug-related adverse events occurred ^{6Reference 6Wolinsky D et al. · 2026Clinical trialSafety, pharmacodynamics, and pharmacokinetics of oral cannabigerol in healthy adults — human studyView study →}.

That is a narrow but genuine foundation: CBG is absorbed orally in a dose-proportional way at commercially realistic doses, and the exposure one person gets from a given milligram figure is a poor predictor of another’s. Chronic dosing has not been studied, and no bioavailability figure against an intravenous reference exists.

Isolate vs. Plant Studies

Everything is the isolate, including both human studies — 20 mg of hemp-derived CBG tincture in one ^{5Reference 5Cuttler C et al. · 2024RCTAcute effects of cannabigerol on anxiety, stress, and mood: a double-blind, placebo-controlled, crossover, field trialView study →}, CBG isolate in oil in the other ^{6Reference 6Wolinsky D et al. · 2026Clinical trialSafety, pharmacodynamics, and pharmacokinetics of oral cannabigerol in healthy adults — human studyView study →}. The colitis and appetite work used purified compound in rodents ^{2,4Reference 2Borrelli F et al. · 2013AnimalBeneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease — mouse colitis modelView study →Reference 4Brierley DI et al. · 2016AnimalCannabigerol is a novel, well-tolerated appetite stimulant in pre-satiated rats — rat feeding modelView study →}.

No trial has tested a CBG-dominant cannabis chemotype, which is the form the plant actually offers, and none has tested CBG alongside the other cannabinoids it naturally accompanies. That matters more here than usual, because CBG is routinely invoked in “entourage” arguments — the claim that minor cannabinoids shape the effect of whole-plant preparations — and no study has yet put that claim to a test with CBG in it.

Its Role in Plants

CBGA is the hub of the cannabinoid pathway rather than an endpoint. A polyketide route builds olivetolic acid; a prenyltransferase attaches geranyl pyrophosphate to give cannabigerolic acid; and the three FAD-dependent synthases then take it in three directions ^{8,9,11Reference 8Taura F et al. · 1996Purification and characterization of cannabidiolic-acid synthase from Cannabis sativa L.: biochemical analysis of a novel enzyme that catalyzes the oxidocyclization of cannabigerolic acid to cannabidiolic acidView study →Reference 9Sirikantaramas S et al. · 2004The gene controlling marijuana psychoactivity: molecular cloning and heterologous expression of Δ1-tetrahydrocannabinolic acid synthase from Cannabis sativa LView study →Reference 11Fulvio F et al. · 2021Analysis of sequence variability and transcriptional profile of cannabinoid synthase genes in Cannabis sativa L. chemotypes with a focus on cannabichromenic acid synthaseView study →}. Everything set out in What “Mother Cannabinoid” Actually Means follows from that single branch point.

Like the other cannabinoids, CBGA accumulates in the glandular trichomes of the female inflorescence, exported out of the secretory cells into a resin cavity. Whether CBGA itself has a defensive role independent of its products is not established; it is present in every chemotype because it has to be, which makes its function hard to separate from its position in the pathway.

Prevalence in Nature

CBG occurs where cannabis does, and essentially nowhere else — one of the hundred-plus phytocannabinoids catalogued from the plant ^{12Reference 12Hanuš LO et al. · 2016ReviewPhytocannabinoids: a unified critical inventory — reviewView study →}, with no other genus an established source.

Its abundance follows an unusual rule. Because CBG is unconverted precursor, its concentration is highest early in flowering and falls as the plant matures, and it is highest of all in cultivars whose downstream synthases are non-functional. In the DEA survey of seized cannabis from 2013 to 2022, CBG was one of only two cannabinoids besides THC to exceed 0.5% of dried material, reaching up to about 1% ^{7Reference 7ElSohly MA et al. · 2024ObservationalA 10-year trend in cannabis potency (2013–2022) in different geographical regions of the United States of America — observationalView study →} — which makes it, in ordinary drug-type cannabis, the third most abundant cannabinoid present.

No percentage figure has been published for CBG-dominant chemotypes, which is where the commercial material comes from, so the upper end of its natural range is not documented.

Major Natural Sources

Source	Part	Level	Note
Drug-type cannabis (Cannabis sativa)	dried female inflorescence	up to ~1%	with CBN, the only cannabinoid besides THC above 0.5% 7Reference 7ElSohly MA et al. · 2024ObservationalA 10-year trend in cannabis potency (2013–2022) in different geographical regions of the United States of America — observationalView study →
Early-harvest cannabis	immature inflorescence	higher than at maturity	unconverted precursor, not yet routed downstream
CBG-dominant cultivars	dried inflorescence	not quantified in the literature	downstream synthases absent or non-functional
Cannabis	leaf, stem, seed, root	negligible	no glandular trichomes to speak of

Discovery & Synthesis

CBG was characterised as one of the neutral cannabinoids in the Weizmann Institute series that also produced THC in 1964 ^{13Reference 13Gaoni Y · 1964Isolation, structure, and partial synthesis of an active constituent of hashishView study →} and revisited the neutral fraction of hashish in detail in 1971 ^{14Reference 14Gaoni Y · 1971Isolation and structure of Δ⁺-tetrahydrocannabinol and other neutral cannabinoids from hashishView study →}. Its significance was not obvious at the time: CBG looked like another minor constituent, and it was only once the biosynthetic pathway was worked out — CBDA synthase in 1996 ^{8Reference 8Taura F et al. · 1996Purification and characterization of cannabidiolic-acid synthase from Cannabis sativa L.: biochemical analysis of a novel enzyme that catalyzes the oxidocyclization of cannabigerolic acid to cannabidiolic acidView study →}, THCA synthase in 2004 ^{9Reference 9Sirikantaramas S et al. · 2004The gene controlling marijuana psychoactivity: molecular cloning and heterologous expression of Δ1-tetrahydrocannabinolic acid synthase from Cannabis sativa LView study →} — that its acid form turned out to be the substrate all of them share.

Production is extraction and breeding rather than synthesis. Commercial CBG comes from cultivars selected to accumulate the precursor, harvested for it directly. That is a comparatively recent agricultural development, and it is why CBG went from a laboratory curiosity to a retail product without passing through a clinical programme.

Patents: not yet researched (future patent-loop pass).

Toxicity & Safety

CBG is non-intoxicating and, in the two human studies published so far, well tolerated. The dose-ranging laboratory study recorded no drug-related adverse events across 25–200 mg and found liver function tests never exceeded the upper limit of normal after the two highest doses ^{6Reference 6Wolinsky D et al. · 2026Clinical trialSafety, pharmacodynamics, and pharmacokinetics of oral cannabigerol in healthy adults — human studyView study →}; the field trial found no subjective drug effects and no measurable motor or cognitive impairment at 20 mg ^{5Reference 5Cuttler C et al. · 2024RCTAcute effects of cannabigerol on anxiety, stress, and mood: a double-blind, placebo-controlled, crossover, field trialView study →}.

That is an acute picture in a total of 46 healthy adults. Chronic dosing has not been studied at all, and no drug-interaction study exists. The interaction concern that follows from the pharmacology is not the cannabinoid one: as a potent α2-adrenoceptor agonist ^{1Reference 1Cascio MG et al. · 2010In vitroEvidence that the plant cannabinoid cannabigerol is a highly potent α2-adrenoceptor agonist and moderately potent 5HT1A receptor antagonist — in vitroView study →}, CBG shares a target with clonidine and dexmedetomidine, so additive effects with blood-pressure medication or sedatives are plausible and untested. As with all cannabis-derived products, commercial CBG preparations vary in purity and labelled content.

Dosage

There is no established human dose for CBG, and nothing here is a recommendation.

The 20 mg figure is the dose at which a benefit was reported once and not replicated; the 25–200 mg range is the dose span across which a controlled study found little. Neither establishes an effective dose. These are doses studied in research and are not a personal recommendation.

References

1. Cascio MG, Gauson LA, Stevenson LA, Ross RA, Pertwee RG (2010). Evidence that the plant cannabinoid cannabigerol is a highly potent α2-adrenoceptor agonist and moderately potent 5HT1A receptor antagonist — in vitro. British Journal of Pharmacology. https://pubmed.ncbi.nlm.nih.gov/20002104/
2. Borrelli F, Fasolino I, Romano B, et al. (2013). Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease — mouse colitis model. Biochemical Pharmacology. https://pubmed.ncbi.nlm.nih.gov/23415610/
3. De Petrocellis L, Ligresti A, Moriello AS, et al. (2011). Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes — in vitro. British Journal of Pharmacology. https://pubmed.ncbi.nlm.nih.gov/21175579/
4. Brierley DI, Samuels J, Duncan M, Whalley BJ, Williams CM (2016). Cannabigerol is a novel, well-tolerated appetite stimulant in pre-satiated rats — rat feeding model. Psychopharmacology (Berl). https://pubmed.ncbi.nlm.nih.gov/27503475/
5. Cuttler C, Stueber A, Cooper ZD, Russo E (2024). Acute effects of cannabigerol on anxiety, stress, and mood: a double-blind, placebo-controlled, crossover, field trial. Scientific Reports. https://pubmed.ncbi.nlm.nih.gov/39003387/
6. Wolinsky D, Srungaram D, Zhang A, et al. (2026). Safety, pharmacodynamics, and pharmacokinetics of oral cannabigerol in healthy adults — human study. Journal of Pharmacology and Experimental Therapeutics. https://pubmed.ncbi.nlm.nih.gov/42575778/
7. ElSohly MA, Majumdar CG, Chandra S, et al. (2024). A 10-year trend in cannabis potency (2013–2022) in different geographical regions of the United States of America — observational. Frontiers in Public Health. https://pubmed.ncbi.nlm.nih.gov/39421827/
8. Taura F, Morimoto S, Shoyama Y (1996). Purification and characterization of cannabidiolic-acid synthase from Cannabis sativa L.: biochemical analysis of a novel enzyme that catalyzes the oxidocyclization of cannabigerolic acid to cannabidiolic acid. Journal of Biological Chemistry. https://pubmed.ncbi.nlm.nih.gov/8663284/
9. Sirikantaramas S, Morimoto S, Shoyama Y, et al. (2004). The gene controlling marijuana psychoactivity: molecular cloning and heterologous expression of Δ1-tetrahydrocannabinolic acid synthase from Cannabis sativa L. Journal of Biological Chemistry. https://pubmed.ncbi.nlm.nih.gov/15190053/
10. Taura F, Sirikantaramas S, Shoyama Y, et al. (2007). Cannabidiolic-acid synthase, the chemotype-determining enzyme in the fiber-type Cannabis sativa. FEBS Letters. https://pubmed.ncbi.nlm.nih.gov/17544411/
11. Fulvio F, Paris R, Montanari M, et al. (2021). Analysis of sequence variability and transcriptional profile of cannabinoid synthase genes in Cannabis sativa L. chemotypes with a focus on cannabichromenic acid synthase. Plants. https://pubmed.ncbi.nlm.nih.gov/34579390/
12. Hanuš LO, Meyer SM, Muñoz E, et al. (2016). Phytocannabinoids: a unified critical inventory — review. Natural Product Reports. https://pubmed.ncbi.nlm.nih.gov/27722705/
13. Gaoni Y, Mechoulam R (1964). Isolation, structure, and partial synthesis of an active constituent of hashish. Journal of the American Chemical Society. https://doi.org/10.1021/ja01062a046
14. Gaoni Y, Mechoulam R (1971). Isolation and structure of Δ⁺-tetrahydrocannabinol and other neutral cannabinoids from hashish. Journal of the American Chemical Society. https://doi.org/10.1021/ja00730a036

View all 14 references▾